Literature DB >> 19154417

Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.

Mari Maegawa1, Tokuzo Arao, Hideyuki Yokote, Kazuko Matsumoto, Kanae Kudo, Kaoru Tanaka, Hiroyasu Kaneda, Yoshihiko Fujita, Fumiaki Ito, Kazuto Nishio.   

Abstract

Constitutively active mutations of epidermal growth factor receptor (EGFR) (delE746_A750) activate downstream signals, such as ERK and Akt, through the phosphorylation of tyrosine residues in the C-terminal region of EGFR. These pathways are thought to be important for cellular sensitivity to EGFR tyrosine kinase inhibitors (TKI). To examine the correlation between phosphorylation of the tyrosine residues in the C-terminal region of EGFR and cellular sensitivity to EGFR TKI, we used wild-type (wt) EGFR, as well as the following constructs: delE746_A750 EGFR; delE746_A750 EGFR with substitution of seven tyrosine residues to phenylalanine in the C-terminal region; and delE746_A750 EGFR with a C-terminal truncation at amino acid 980. These constructs were transfected stably into HEK293 cells and designated HEK293/Wt, HEK293/D, HEK293/D7F, and HEK293/D-Tr, respectively. The HEK293/D cells were found to be 100-fold more sensitive to EGFR TKI (AG1478) than HEK293/Wt. Surprisingly, the HEK293/D7F and HEK293/D-Tr cells, transfected with EGFR lacking the C-terminal autophosphorylation sites, retained high sensitivity to EGFR TKI. In these three high-sensitivity cells, the ERK pathway was activated without ligand stimulation, which was inhibited by EGFR TKI. In addition, although EGFR in the HEK293/D7F and HEK293/D-Tr cells lacked significant tyrosine residues for EGFR signal transduction, phosphorylation of Src homology and collagen homology (Shc) was spontaneously activated in these cells. Our results indicate that tyrosine residues in the C-terminal region of EGFR are not required for cellular sensitivity to EGFR TKI, and that an as-yet-unknown signaling pathway of EGFR may exist that is independent of the C-terminal region of EGFR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154417     DOI: 10.1111/j.1349-7006.2008.01071.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers.

Authors:  Weina Ma; Dongdong Zhang; Lei Zheng; Yingzhuan Zhan; Yanmin Zhang
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

2.  Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

Authors:  Ykelien L Boersma; Ginger Chao; Daniel Steiner; K Dane Wittrup; Andreas Plückthun
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

3.  Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Authors:  Jeonghee Cho; Liang Chen; Naveen Sangji; Takafumi Okabe; Kimio Yonesaka; Joshua M Francis; Richard J Flavin; William Johnson; Jihyun Kwon; Soyoung Yu; Heidi Greulich; Bruce E Johnson; Michael J Eck; Pasi A Jänne; Kwok-Kin Wong; Matthew Meyerson
Journal:  Cancer Res       Date:  2013-09-24       Impact factor: 12.701

4.  Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells.

Authors:  Anping Gui; Akira Kobayashi; Hiroaki Motoyama; Masato Kitazawa; Michiko Takeoka; Shinichi Miyagawa
Journal:  BMC Cancer       Date:  2012-05-16       Impact factor: 4.430

5.  Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.

Authors:  Angela K J Park; Joshua M Francis; Woong-Yang Park; Joon-Oh Park; Jeonghee Cho
Journal:  Oncotarget       Date:  2015-04-20

6.  Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Authors:  Eri Banno; Yosuke Togashi; Yu Nakamura; Masato Chiba; Yoshihisa Kobayashi; Hidetoshi Hayashi; Masato Terashima; Marco A de Velasco; Kazuko Sakai; Yoshihiko Fujita; Tetsuya Mitsudomi; Kazuto Nishio
Journal:  Cancer Sci       Date:  2016-07-14       Impact factor: 6.716

7.  Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.

Authors:  Jeonghee Cho; Sujin Kim; Jinyan Du; Matthew Meyerson
Journal:  Int J Cancer       Date:  2018-03-05       Impact factor: 7.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.